Full history for every metric is available with a Kvantra account

Stock profile
Moderna, Inc. logo

Moderna, Inc. (MRNA)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
79.7B
Currency USD
KvantraRankAbout31
IValue10
IIQuality5
IIIMomentum100
Current price
196.79 USD-4.84%
Close 18 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$bn0.817.718.96.83.21.92.52.3
Operating profit$bn-3.07-2.93
Net profit$bn-0.712.28.4-4.7-3.6-2.8-2.8-2.9
EPS reported$-7.26-7.10
Operating cashflow per share$-4.81-4.45
Capex per share$0.490.46
FCF per share$-5.31-4.91
Free cash flow$bn-2.07-1.97
Net debt$bn-4.56-1.62
Book value equity$bn8.656.84
Book value per share$22.2415.90
Number of sharesm389430
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx--
P/B LTMx1.3311.66
P/S LTMx5.9031.57
P/FCF LTMx-5.56-40.46
EV/EBITDA LTMx-4.23-31.80
EV/Sales LTMx5.2430.92
Earnings Yield LTM%-24.60%-3.36%
FCF Yield%-18.00%-2.47%
Quality
ROE%-32.62%-37.62%
ROIC%-29.58%-25.61%
Operating margin%-158.13%-116.04%
Gross margin%55.35%28.00%
FCF/Sales%-106.22%-78.02%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%-39.23%+13.69%
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%--
FCF/Debtx-1.08-0.47
Net Debt/EBITDAx0.51-1.22
EBIT/Net interestx-307.40-117.20
Net debt/market cap%-39.72%-2.04%
Net debt/Equityx-0.53-0.24
Gross debt/equityx0.220.61

ETFs that hold Moderna

FundTickerPosition#Weight
Invesco S&P 500 Equal Weight ETFRSP10.33%
Vanguard Morningstar Small-Cap ETFVB80.44%
iShares Russell Mid-Cap ETFIWR50.61%
Vanguard Morningstar Small-Cap Value ETFVBR10.79%
Xtrackers S&P 500 Equal Weight UCITS ETF 1CXDEW.L10.33%
iShares Russell Mid-Cap Value ETFIWS20.81%
iShares Biotechnology ETFIBB55.84%
State Street SPDR S&P Biotech ETFXBI12.55%
iShares MSCI World Small Cap UCITS ETFIUSN.DE10.75%
iShares S&P 500 Equal Weight UCITS ETF USD (Acc)EWSP.L10.33%

Funds with Moderna among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price196.79 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Moderna, Inc. (MRNA)

MRNA · NASDAQ · Healthcare
196.79 USD-4.84%
Sign up to track this stock
Benchmarks
KvantraRank31
Market cap79.7B
P/E NTMN/A
P/E TTMN/A
KvantraRank?31 / 100
Value
10
Quality
5
Momentum
100
Financialsin USD
20242025TTM2026E
ETFs that hold Moderna
FundTickerPosition#Weight
Invesco S&P 500 Equal Weight ETFRSP10.33%
Vanguard Morningstar Small-Cap ETFVB80.44%
iShares Russell Mid-Cap ETFIWR50.61%
Vanguard Morningstar Small-Cap Value ETFVBR10.79%
Xtrackers S&P 500 Equal Weight UCITS ETF 1CXDEW.L10.33%
iShares Russell Mid-Cap Value ETFIWS20.81%
iShares Biotechnology ETFIBB55.84%
State Street SPDR S&P Biotech ETFXBI12.55%
iShares MSCI World Small Cap UCITS ETFIUSN.DE10.75%
iShares S&P 500 Equal Weight UCITS ETF USD (Acc)EWSP.L10.33%

Funds with Moderna among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current196.79 USD
Upside
Price consensus
Last year average price target
Current price196.79 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free